Verve Therapeutics (VERV) Stock Price, News & Analysis

Company Overview

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $4.20 to $4.44
• 50-Day Range: $2.97 to $5.84
• 52-Week Range: $2.86 to $9.31
• Volume: 2.75 million shs
• Average Volume: 1.87 million shs
• Market Capitalization: $377.97 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.75
• Consensus Rating: Buy

Verve Therapeutics Stock Analysis - MarketRank™

Verve Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 359th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Verve Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Verve Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Verve Therapeutics are expected to decrease in the coming year, from ($2.49) to ($2.83) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Verve Therapeutics is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Verve Therapeutics is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Verve Therapeutics has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

28.00% of the float of Verve Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Verve Therapeutics has a short interest ratio ("days to cover") of 6.1.

Change versus previous month

Short interest in Verve Therapeutics has recently decreased by 0.54%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Verve Therapeutics does not currently pay a dividend.

Dividend Growth

Verve Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

28.00% of the float of Verve Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Verve Therapeutics has a short interest ratio ("days to cover") of 6.1.

Change versus previous month

Short interest in Verve Therapeutics has recently decreased by 0.54%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.88

News Sentiment

Verve Therapeutics has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for Verve Therapeutics this week, compared to 6 articles on an average week.

Search Interest

Only 15 people have searched for VERV on MarketBeat in the last 30 days. This is a decrease of -12% compared to the previous 30 days.

MarketBeat Follows

7 people have added Verve Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Verve Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $25,427.00 in company stock.

Percentage Held by Insiders

19.90% of the stock of Verve Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

97.11% of the stock of Verve Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VERV Stock Analysis - Frequently Asked Questions

How have VERV shares performed this year?

Verve Therapeutics' stock was trading at $5.64 at the beginning of the year. Since then, VERV stock has decreased by 24.8% and is now trading at $4.24.
View the best growth stocks for 2025 here.

How were Verve Therapeutics' earnings last quarter?

Verve Therapeutics, Inc. (NASDAQ:VERV) announced its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.36. The business earned $32.98 million during the quarter, compared to analyst estimates of $7.13 million. Verve Therapeutics had a negative trailing twelve-month return on equity of 35.23% and a negative net margin of 807.65%.

When did Verve Therapeutics IPO?

Verve Therapeutics (VERV) raised $201 million in an initial public offering on Thursday, June 17th 2021. The company issued 11,800,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair acted as the underwriters for the IPO.

Who are Verve Therapeutics' major shareholders?

Verve Therapeutics' top institutional shareholders include Vanguard Group Inc. (4.44%), Woodline Partners LP (3.10%), T. Rowe Price Investment Management Inc. (2.80%) and Millennium Management LLC (2.37%). Insiders that own company stock include Krishna Yeshwant, Fmr Llc, Andrew D Ashe, Sekar Kathiresan, Joan Nickerson, Allison Dorval, Andrew Bellinger and 2017 Gp LLC Gv.
View institutional ownership trends.

How do I buy shares of Verve Therapeutics?

Shares of VERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Verve Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Verve Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 5/28/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VERV
• CIK: 1840574
• Web: vervetx.com
• Phone: 617-603-0070
• Fax: N/A
• Employees: 110
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $25.75
• High Stock Price Target: $39.00
• Low Stock Price Target: $15.00
• Potential Upside/Downside: +500.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$200.07 million
• Net Margins: -807.65%
• Pretax Margin: -806.39%
• Return on Equity: -35.23%
• Return on Assets: -27.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.05
• Quick Ratio: 13.05

Sales & Book Value

• Annual Sales: $59.61 million
• Price / Sales: 6.41
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.31 per share
• Price / Book: 0.59

Miscellaneous

• Outstanding Shares: 89,143,000
• Free Float: 68,324,000
• Market Cap: $382.16 million
• Optionable: Optionable
• Beta: 1.82